Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Y-box-binding protein 3 (YBX3), also known as ZONAB, DbpA, and CSDA, is a multifunctional cold shock domain-containing protein that binds DNA and RNA, acting primarily as a transcriptional and post-transcriptional regulator. In epithelial cells, YBX3 dynamically shuttles between tight junctions and the nucleus, where it regulates genes critical for cell cycle progression, cellular differentiation, and responses to environmental stress. YBX3 binds mRNA (including 3′-UTRs of key transcripts) to stabilize and enhance their translation, influencing proliferation and apoptosis. Dysregulation of YBX3 is implicated in the pathogenesis and progression of multiple malignancies, where its overexpression is linked to enhanced proliferation, invasion, and chemoresistance. Recent studies demonstrate roles in tumor immune evasion, regulation of epithelial–mesenchymal transition, and potential antiviral activity against influenza A virus
Not applicable (no drugs directly targeting YBX3 identified)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Y-box-binding protein 3 (YBX3).